Cellectar Biosciences (CLRB) director receives grant of 25,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. According to the terms, the entire grant will vest on July 7, 2027, provided he continues to serve through that date. Following this grant, his reported holdings include 25,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chanan-Khan Asher
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 25,000 options
Exercise price: $2.70 per share
Expiration date: July 7, 2036
+2 more
5 metrics
Options granted
25,000 options
Stock option grant to director Asher Chanan-Khan
Exercise price
$2.70 per share
Strike price for the 25,000 stock options
Expiration date
July 7, 2036
Options expire if not exercised by this date
Vesting date
July 7, 2027
Options vest in full on this date, subject to service
Options held after grant
25,000 options
Total reported derivative holdings following transaction
Key Terms
Stock option (right to buy), exercise price, expiration date, vest in full, +1 more
5 terms
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "2.7000" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-07-07T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in full financial
"This option shall vest in full on July 7, 2027"
continued service financial
"subject to the reporting person's continued service through the applicable vesting date"
FAQ
What insider transaction did Cellectar Biosciences (CLRB) report for Asher Chanan-Khan?
Cellectar Biosciences reported a grant of stock options to director Asher Chanan-Khan. He received options on 25,000 shares of common stock as compensation, not a market purchase, with a defined exercise price and long-term expiration date.
How many Cellectar Biosciences (CLRB) options were granted to Asher Chanan-Khan?
Asher Chanan-Khan was granted stock options on 25,000 shares of Cellectar Biosciences common stock. This entire amount is tied to a single grant and represents his reported option position following the transaction on the Form 4 filing date.
What is the exercise price of Asher Chanan-Khan’s CLRB stock options?
The exercise price of the granted stock options is $2.70 per share. This means he can buy Cellectar Biosciences common stock at $2.70 if the options vest and are exercised before they expire, subject to the vesting conditions.
When do Asher Chanan-Khan’s Cellectar Biosciences options vest?
The options will vest in full on July 7, 2027. Vesting is conditional on his continued service with Cellectar Biosciences through that date, so the grant is structured as long-term, service-based compensation for his role as a director.
When do Asher Chanan-Khan’s CLRB stock options expire?
The granted stock options expire on July 7, 2036. After this expiration date, any unexercised options become worthless, so potential use of this award is limited to the period between vesting in 2027 and expiration in 2036.